(Q37240710)

English

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

scientific article published on 13 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Martine Piccart-Gebhart

13

object named as

Martine Piccart-Gebhart

0 references

Evandro de Azambuja

4

object named as

Evandro de Azambuja

0 references

1

object named as

Mitch Dowsett

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

11

object named as

Giuseppe Viale

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Marion Procter

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Worta McCaskill-Stevens

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Urania Dafni

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Josef Rueschoff

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bruce Jordan

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stella Dolci

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mark Abramovitz

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Oliver Stoss

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Richard D Gelber

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Brian Leyland-Jones

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

13 April 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

2962-2969

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

6 September 2017

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2701645

3 September 2018

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19364966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19364966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

https://pubmed.ncbi.nlm.nih.gov/19364966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19364966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.7939

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37240710&oldid=2180863480"